Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail | Zendy

Boom Louisa | Zendy; Stuecher Theresa | Zendy; Mader Julia K. | Zendy

Open Access

Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail

Author(s) -

Boom Louisa,

Stuecher Theresa,

Mader Julia K.

Publication year - 2021

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.4811

Subject(s) - medicine , dulaglutide , glycemic , type 2 diabetes , glucagon like peptide 1 receptor , girl , agonist , intensive care medicine , glucagon like peptide 1 , pediatrics , diabetes mellitus , endocrinology , exenatide , insulin , receptor , psychology , developmental psychology

This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research